Trials
2 active
4 in total · 2 in the EU
What this is
- How it works
- A short strand of RNA that switches off one gene, so the body makes less of one protein.-siran: small interfering RNA WHO name stem
- Tested for
- Homozygous Familial Hypercholesterolemia (2 trials)
- Main trialPhase 3
- “This multicenter, randomized, placebo-controlled study will evaluate the efficacy and safety of zodasiran subcutaneous (SC) injection in subjects 12 years of age and older with genetically or clinically diagnosed Homozygous familial hypercholesterolemia (HoFH). After completion of the double blind (DB) treatment period subjects will be eligible to continue in the optional open-label extension (OLE) period of the study. All placebo subjects who opt to continue will transition to active drug during the OLE Period.”In the company’s words, NCT07037771 on ClinicalTrials.gov
- Other names
- ARO-ANG3
Other drugs for Homozygous Familial Hypercholesterolemia
- InclisiranNovartis Pharmaceuticals · Phase 3
- VSA003Visirna Therapeutics HK Limited · Phase 3
- EDP167Eddingpharm (Zhuhai) Co., Ltd. · Phase 2
- SHR-1918Hengrui · Phase 2
- CTX310CRISPR Therapeutics AG · Phase 1
Coming up2
- 20 Aug 2027Phase 3 trial completes · ClinicalTrials.gov
- Jul 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 20 Aug 2027 | A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE) | |
| Phase 3Recruiting | Jul 2028 | Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemia | |
| Phase 2Completed | 30 Aug 2022 | Study of ARO-ANG3 in Adults With Mixed Dyslipidemia | |
| Phase 1Completed | 17 May 2021 | Study of ARO-ANG3 in Healthy Volunteers and in Dyslipidemic Patients |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026